FDA Regulations on Medical Devices Tighten, Emphasis on Long-Term Control

On February 2, 2026, the FDA pushed their new Quality Management System Regulation (QMSR), amending 21 CFR Part 820 by incorporating ISO 13485. In other words, the FDA is tightening its regulations on U.S. medical devices, now more closely aligning with the global standards many device companies already use. QMSR is replacing the old Quality System Inspection Technique (QSIT).

What regulators will look at

With this longer-term, more controlled system, medical device manufacturers should expect regulators to start looking at design controls, manufacturing controls, supplier controls, software, cybersecurity, updates, complaints, corrective actions, and post-market monitoring as one integrated quality-check system.

Cybersecurity is now part of the submission

The FDA is tightening expectations around the entire product lifecycle, and this should be seen as a trend rather than one isolated change. In conjunction with QMSR, the FDA also issued updated 2026 guidance on cyber devices, pushing medical device makers to include cybersecurity documentation in their approval paperwork before selling. Under FD&C Act section 524B, cyber-device submissions now require more rigorous documentation and planning. This includes, but is not limited to, plans to monitor and address post-market vulnerabilities, processes to keep the device cybersecure, and post-market patching capabilities.

Compliance is now a lifecycle, not a launch

With these FDA changes, the direction is clear: regulators care increasingly about manufacturers proving they have a long-term plan for their product. Compliance is no longer an at-launch to-do item but something companies must systematically monitor post-deployment.